Details of the Drug Combinations

General Information of This Drug (ID: DMSE3I7)

• Drug Name: Gemcitabine (DMSE3I7)
• Synonyms: Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)

Indication

Anterior urethra cancer; ICD 11: N.A.; Status: Approved [1]; Biliary tract cancer; ICD 11: 2C17; Status: Approved [1]; Carcinoma; ICD 11: 2A00-2F9Z; Status: Approved [1]; Cervical cancer; ICD 11: 2C77.0; Status: Approved [1]; Cholangiocarcinoma; ICD 11: 2C12.10; Status: Approved [1]; Fallopian tube neoplasm; ICD 11: N.A.; Status: Approved [1]; Gallbladder carcinoma; ICD 11: N.A.; Status: Approved [1]; Leiomyosarcoma; ICD 11: 2B58; Status: Approved [1]; Leukemia; ICD 11: N.A.; Status: Approved [1]; Lung cancer; ICD 11: 2C25.0; Status: Approved [1]; MALT lymphoma; ICD 11: N.A.; Status: Approved [1]; Nodal marginal zone lymphoma; ICD 11: 2A85.0; Status: Approved [1]; Non-small-cell lung cancer; ICD 11: 2C25; Status: Approved [2]; Ovarian disorder; ICD 11: N.A.; Status: Approved [1]; Ovarian neoplasm; ICD 11: N.A.; Status: Approved [1]; Pancreatic adenocarcinoma; ICD 11: N.A.; Status: Approved [1]; Pancreatic ductal carcinoma; ICD 11: 2C10.0; Status: Approved [1]; Pancreatic tumour; ICD 11: 2C10; Status: Approved [1]; Posterior urethra cancer; ICD 11: N.A.; Status: Approved [1]; Recurrent adult burkitt lymphoma; ICD 11: 2A85.6; Status: Approved [1]; Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Approved [3]; Splenic marginal zone lymphoma; ICD 11: N.A.; Status: Approved [1]; Urethral cancer; ICD 11: 2C93; Status: Approved [1]; Urinary bladder neoplasm; ICD 11: N.A.; Status: Approved [1]; Middle East Respiratory Syndrome (MERS); ICD 11: 1D64; Status: Preclinical [4]; Severe acute respiratory syndrome (SARS); ICD 11: 1D65; Status: Preclinical [4]; Colon cancer; ICD 11: 2B90.Z; Status: Investigative [1]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

317 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Abexinostat + Gemcitabine	DCGCFJX	Abexinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
ATI-17000 + Gemcitabine	DCYV04Q	ATI-17000	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
CF102 + Gemcitabine	DCY462G	CF102	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Citarinostat + Gemcitabine	DC4ABNM	Citarinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Fluorouracil + Gemcitabine	DCU1EKM	Fluorouracil	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[6]
Fluorouracil + Gemcitabine	DCM7JP9	Fluorouracil	Colon carcinoma (Cell Line: RKO)	[6]
Fluorouracil + Gemcitabine	DCAHIF1	Fluorouracil	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Fluorouracil + Gemcitabine	DCDI7RL	Fluorouracil	Adenocarcinoma (Cell Line: CAOV3)	[7]
Fluorouracil + Gemcitabine	DCZV1CV	Fluorouracil	Adenocarcinoma (Cell Line: A427)	[7]
Fluorouracil + Gemcitabine	DC8XZDL	Fluorouracil	Adenocarcinoma (Cell Line: NCIH23)	[7]
Fluorouracil + Gemcitabine	DCI7OR3	Fluorouracil	Adenocarcinoma (Cell Line: NCIH520)	[7]
Fluorouracil + Gemcitabine	DC3DDW2	Fluorouracil	Adenocarcinoma (Cell Line: HT29)	[7]
Fluorouracil + Gemcitabine	DCA53PF	Fluorouracil	Germ cell tumour (Cell Line: PA1)	[7]
Fluorouracil + Gemcitabine	DC942A5	Fluorouracil	Large cell lung carcinoma (Cell Line: NCI-H460)	[7]
Fluorouracil + Gemcitabine	DC34U36	Fluorouracil	Malignant melanoma (Cell Line: RPMI7951)	[7]
Fluorouracil + Gemcitabine	DCSVNOF	Fluorouracil	Malignant melanoma (Cell Line: SKMEL30)	[7]
Fluorouracil + Gemcitabine	DCENY78	Fluorouracil	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[7]
Gemcitabine + Ruxolitinib	DCNWB2P	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[5]
Gemcitabine + Ruxolitinib	DCFR80Q	Ruxolitinib	T-cell leukemia/lymphoma (Cell Line: ED-40515)	[5]
Gemcitabine + PD-0325901	DC8IYM5	PD-0325901	Adenocarcinoma (Cell Line: CAOV3)	[5]
Gemcitabine + PD-0325901	DCERP08	PD-0325901	Adenocarcinoma (Cell Line: OVCAR3)	[5]
Gemcitabine + PD-0325901	DC06QZF	PD-0325901	Adenocarcinoma (Cell Line: A427)	[5]
Gemcitabine + PD-0325901	DCD4O3Y	PD-0325901	Adenocarcinoma (Cell Line: NCIH1650)	[5]
Gemcitabine + PD-0325901	DCAKIQH	PD-0325901	Adenocarcinoma (Cell Line: NCIH2122)	[5]
Gemcitabine + PD-0325901	DCOEZF7	PD-0325901	Adenocarcinoma (Cell Line: NCIH23)	[5]
Gemcitabine + PD-0325901	DCA5QDO	PD-0325901	Adenocarcinoma (Cell Line: NCIH520)	[5]
Gemcitabine + PD-0325901	DC6HX4S	PD-0325901	Adenocarcinoma (Cell Line: COLO320DM)	[5]
Gemcitabine + PD-0325901	DCMTFK2	PD-0325901	Adenocarcinoma (Cell Line: DLD1)	[5]
Gemcitabine + PD-0325901	DCPFL52	PD-0325901	Adenocarcinoma (Cell Line: HCT116)	[5]
Gemcitabine + PD-0325901	DC4QGK2	PD-0325901	Adenocarcinoma (Cell Line: HT29)	[5]
Gemcitabine + PD-0325901	DCBRYAF	PD-0325901	Adenocarcinoma (Cell Line: SW-620)	[5]
Gemcitabine + PD-0325901	DC1VG1L	PD-0325901	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + PD-0325901	DCK5EPB	PD-0325901	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[5]
Gemcitabine + PD-0325901	DCS1YO6	PD-0325901	Germ cell tumour (Cell Line: PA1)	[5]
Gemcitabine + PD-0325901	DCSZ5YI	PD-0325901	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Gemcitabine + PD-0325901	DCNLK8Z	PD-0325901	Malignant melanoma (Cell Line: HT144)	[5]
Gemcitabine + PD-0325901	DCN0PBY	PD-0325901	Malignant melanoma (Cell Line: RPMI7951)	[5]
Gemcitabine + PD-0325901	DCPY9O3	PD-0325901	Malignant melanoma (Cell Line: SKMEL30)	[5]
Gemcitabine + PD-0325901	DCUQFUZ	PD-0325901	Malignant melanoma (Cell Line: UACC62)	[5]
Gemcitabine + PD-0325901	DC6DEPA	PD-0325901	Malignant melanoma (Cell Line: A375)	[5]
Gemcitabine + PD-0325901	DC96ZT4	PD-0325901	Mesothelioma (Cell Line: MSTO)	[5]
Gemcitabine + PD-0325901	DCMGWJY	PD-0325901	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[5]
Gemcitabine + PD-0325901	DCX2USE	PD-0325901	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Gemcitabine + PD-0325901	DCU7I8B	PD-0325901	Prostate carcinoma (Cell Line: LNCAP)	[5]
Gemcitabine + PD-0325901	DC0PV2N	PD-0325901	Prostate carcinoma (Cell Line: VCAP)	[5]
Gemcitabine + Lapatinib	DCU3BNY	Lapatinib	Adenocarcinoma (Cell Line: A427)	[5]
Gemcitabine + Lapatinib	DC2AP8F	Lapatinib	Adenocarcinoma (Cell Line: NCIH2122)	[5]
Gemcitabine + Lapatinib	DCOWZBF	Lapatinib	Adenocarcinoma (Cell Line: COLO320DM)	[5]
Gemcitabine + Lapatinib	DC91KLD	Lapatinib	Adenocarcinoma (Cell Line: HT29)	[5]
Gemcitabine + Lapatinib	DC8FD8N	Lapatinib	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + MK-1775	DCQ8TLR	MK-1775	Adenocarcinoma (Cell Line: CAOV3)	[5]
Gemcitabine + MK-1775	DCX1ABW	MK-1775	Adenocarcinoma (Cell Line: NCIH2122)	[5]
Gemcitabine + MK-1775	DCJSNJA	MK-1775	Adenocarcinoma (Cell Line: NCIH520)	[5]
Gemcitabine + MK-1775	DCTQC6C	MK-1775	Adenocarcinoma (Cell Line: HT29)	[5]
Gemcitabine + MK-1775	DCZTHLV	MK-1775	Germ cell tumour (Cell Line: PA1)	[5]
Gemcitabine + MK-1775	DC7TP9G	MK-1775	Malignant melanoma (Cell Line: RPMI7951)	[5]
Gemcitabine + MK-1775	DCMJYJF	MK-1775	Malignant melanoma (Cell Line: UACC62)	[5]
Gemcitabine + MK-1775	DCNDQON	MK-1775	Prostate carcinoma (Cell Line: VCAP)	[5]
Gemcitabine + Panobinostat	DCU9J4O	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Gemcitabine + RTB101	DCURN6F	RTB101	Adenocarcinoma (Cell Line: A427)	[5]
Gemcitabine + RTB101	DCOUWPX	RTB101	Adenocarcinoma (Cell Line: NCIH2122)	[5]
Gemcitabine + RTB101	DC8C3F2	RTB101	Adenocarcinoma (Cell Line: NCIH520)	[5]
Gemcitabine + RTB101	DC144E2	RTB101	Adenocarcinoma (Cell Line: COLO320DM)	[5]
Gemcitabine + RTB101	DCAY25C	RTB101	Adenocarcinoma (Cell Line: DLD1)	[5]
Gemcitabine + RTB101	DC38ZID	RTB101	Adenocarcinoma (Cell Line: HT29)	[5]
Gemcitabine + RTB101	DC9FS1E	RTB101	Adenocarcinoma (Cell Line: SW-620)	[5]
Gemcitabine + RTB101	DCA74AI	RTB101	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + RTB101	DC05ROP	RTB101	Germ cell tumour (Cell Line: PA1)	[5]
Gemcitabine + RTB101	DC8VR38	RTB101	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Gemcitabine + RTB101	DCIO6IT	RTB101	Malignant melanoma (Cell Line: HT144)	[5]
Gemcitabine + RTB101	DCREE44	RTB101	Malignant melanoma (Cell Line: RPMI7951)	[5]
Gemcitabine + RTB101	DCXEANM	RTB101	Malignant melanoma (Cell Line: SKMEL30)	[5]
Gemcitabine + RTB101	DC16KGZ	RTB101	Malignant melanoma (Cell Line: UACC62)	[5]
Gemcitabine + RTB101	DC816D2	RTB101	Mesothelioma (Cell Line: MSTO)	[5]
Gemcitabine + RTB101	DC38TIG	RTB101	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Gemcitabine + RTB101	DCJDHAH	RTB101	Prostate carcinoma (Cell Line: LNCAP)	[5]
Gemcitabine + RTB101	DCK6IXC	RTB101	Prostate carcinoma (Cell Line: VCAP)	[5]
Gemcitabine + SCH-900776	DCA7BPX	SCH-900776	Adenocarcinoma (Cell Line: CAOV3)	[5]
Gemcitabine + SCH-900776	DC6SQEX	SCH-900776	Adenocarcinoma (Cell Line: OVCAR3)	[5]
Gemcitabine + SCH-900776	DCHNTC2	SCH-900776	Adenocarcinoma (Cell Line: A427)	[5]
Gemcitabine + SCH-900776	DCI40AC	SCH-900776	Adenocarcinoma (Cell Line: NCIH1650)	[5]
Gemcitabine + SCH-900776	DCRAZV5	SCH-900776	Adenocarcinoma (Cell Line: NCIH2122)	[5]
Gemcitabine + SCH-900776	DCMDXDY	SCH-900776	Adenocarcinoma (Cell Line: NCIH23)	[5]
Gemcitabine + SCH-900776	DCEMQ57	SCH-900776	Adenocarcinoma (Cell Line: NCIH520)	[5]
Gemcitabine + SCH-900776	DC7A0NJ	SCH-900776	Adenocarcinoma (Cell Line: COLO320DM)	[5]
Gemcitabine + SCH-900776	DC7HWO9	SCH-900776	Adenocarcinoma (Cell Line: DLD1)	[5]
Gemcitabine + SCH-900776	DCMEAFV	SCH-900776	Adenocarcinoma (Cell Line: HT29)	[5]
Gemcitabine + SCH-900776	DCG1H5Y	SCH-900776	Adenocarcinoma (Cell Line: SW-620)	[5]
Gemcitabine + SCH-900776	DC27FNX	SCH-900776	Adenocarcinoma (Cell Line: HCT116)	[5]
Gemcitabine + SCH-900776	DCMSYLS	SCH-900776	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + SCH-900776	DC4C4MK	SCH-900776	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[5]
Gemcitabine + SCH-900776	DCM5CK1	SCH-900776	Germ cell tumour (Cell Line: PA1)	[5]
Gemcitabine + SCH-900776	DCXV3MY	SCH-900776	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Gemcitabine + SCH-900776	DCWTVMY	SCH-900776	Malignant melanoma (Cell Line: HT144)	[5]
Gemcitabine + SCH-900776	DC8JB9U	SCH-900776	Malignant melanoma (Cell Line: RPMI7951)	[5]
Gemcitabine + SCH-900776	DC8DSR2	SCH-900776	Malignant melanoma (Cell Line: SKMEL30)	[5]
Gemcitabine + SCH-900776	DCH60LK	SCH-900776	Malignant melanoma (Cell Line: UACC62)	[5]
Gemcitabine + SCH-900776	DC99DAI	SCH-900776	Malignant melanoma (Cell Line: A375)	[5]
Gemcitabine + SCH-900776	DC6XN1G	SCH-900776	Mesothelioma (Cell Line: MSTO)	[5]
Gemcitabine + SCH-900776	DCKYSBK	SCH-900776	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[5]
Gemcitabine + SCH-900776	DC88RCK	SCH-900776	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Gemcitabine + SCH-900776	DCOA8LO	SCH-900776	Prostate carcinoma (Cell Line: LNCAP)	[5]
Gemcitabine + SCH-900776	DCDT16R	SCH-900776	Prostate carcinoma (Cell Line: VCAP)	[5]
Gemcitabine + SNX-2112	DCS6MFI	SNX-2112	Adenocarcinoma (Cell Line: A427)	[5]
Gemcitabine + SNX-2112	DCYDDHZ	SNX-2112	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + SNX-2112	DC1AMZW	SNX-2112	Germ cell tumour (Cell Line: PA1)	[5]
Gemcitabine + SNX-2112	DCS1WU9	SNX-2112	Malignant melanoma (Cell Line: HT144)	[5]
Gemcitabine + SNX-2112	DCS6EDV	SNX-2112	Malignant melanoma (Cell Line: RPMI7951)	[5]
Gemcitabine + SNX-2112	DCZNIMO	SNX-2112	Malignant melanoma (Cell Line: SKMEL30)	[5]
Gemcitabine + SCH 727965	DC8G2TR	SCH 727965	Adenocarcinoma (Cell Line: CAOV3)	[5]
Gemcitabine + SCH 727965	DCV8BP8	SCH 727965	Adenocarcinoma (Cell Line: A427)	[5]
Gemcitabine + SCH 727965	DCENKJY	SCH 727965	Adenocarcinoma (Cell Line: COLO320DM)	[5]
Gemcitabine + SCH 727965	DC4O12U	SCH 727965	Adenocarcinoma (Cell Line: HT29)	[5]
Gemcitabine + SCH 727965	DCIAKW1	SCH 727965	Adenocarcinoma (Cell Line: SW-620)	[5]
Gemcitabine + SCH 727965	DC3SIAH	SCH 727965	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + SCH 727965	DCCD42H	SCH 727965	Germ cell tumour (Cell Line: PA1)	[5]
Gemcitabine + SCH 727965	DC2J54O	SCH 727965	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Gemcitabine + SCH 727965	DC2OECQ	SCH 727965	Malignant melanoma (Cell Line: HT144)	[5]
Gemcitabine + SCH 727965	DC18VO9	SCH 727965	Malignant melanoma (Cell Line: RPMI7951)	[5]
Gemcitabine + SCH 727965	DCQB3UW	SCH 727965	Malignant melanoma (Cell Line: SKMEL30)	[5]
Gemcitabine + SCH 727965	DCVAHN6	SCH 727965	Malignant melanoma (Cell Line: UACC62)	[5]
Gemcitabine + Erlotinib	DCBWPY0	Erlotinib	Adenocarcinoma (Cell Line: A427)	[5]
Gemcitabine + Erlotinib	DCQH8VI	Erlotinib	Adenocarcinoma (Cell Line: NCIH2122)	[5]
Gemcitabine + Erlotinib	DC91R2U	Erlotinib	Adenocarcinoma (Cell Line: NCIH520)	[5]
Gemcitabine + Erlotinib	DC8HVXM	Erlotinib	Adenocarcinoma (Cell Line: COLO320DM)	[5]
Gemcitabine + Erlotinib	DCORV6W	Erlotinib	Adenocarcinoma (Cell Line: DLD1)	[5]
Gemcitabine + Erlotinib	DC8IUHE	Erlotinib	Adenocarcinoma (Cell Line: HT29)	[5]
Gemcitabine + Erlotinib	DC9W669	Erlotinib	Adenocarcinoma (Cell Line: SW-620)	[5]
Gemcitabine + Erlotinib	DCP3927	Erlotinib	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + Erlotinib	DCCQU7I	Erlotinib	Germ cell tumour (Cell Line: PA1)	[5]
Gemcitabine + Erlotinib	DCG1YHA	Erlotinib	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Gemcitabine + Erlotinib	DCQ4FWJ	Erlotinib	Malignant melanoma (Cell Line: HT144)	[5]
Gemcitabine + Erlotinib	DCZAQPJ	Erlotinib	Malignant melanoma (Cell Line: SKMEL30)	[5]
Gemcitabine + Erlotinib	DCRFBS7	Erlotinib	Malignant melanoma (Cell Line: UACC62)	[5]
Gemcitabine + Erlotinib	DCMXYEZ	Erlotinib	Mesothelioma (Cell Line: MSTO)	[5]
Gemcitabine + Erlotinib	DCH6LPN	Erlotinib	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[5]
Gemcitabine + Erlotinib	DCICFF1	Erlotinib	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Gemcitabine + Erlotinib	DC3RJXF	Erlotinib	Prostate carcinoma (Cell Line: LNCAP)	[5]
Gemcitabine + MK-5108	DCWDZPD	MK-5108	Adenocarcinoma (Cell Line: CAOV3)	[5]
Gemcitabine + MK-5108	DCKORVQ	MK-5108	Adenocarcinoma (Cell Line: NCIH520)	[5]
Gemcitabine + MK-5108	DC5CQA5	MK-5108	Adenocarcinoma (Cell Line: DLD1)	[5]
Gemcitabine + MK-5108	DCC6CDR	MK-5108	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + MK-5108	DC2N4XJ	MK-5108	Malignant melanoma (Cell Line: HT144)	[5]
Gemcitabine + MK-5108	DCYK8UU	MK-5108	Non small cell carcinoma (Cell Line: SKMES1)	[5]
Gemcitabine + AG-881	DCDM9ZK	AG-881	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Gemcitabine + Ridaforolimus	DC5EGK9	Ridaforolimus	Adenocarcinoma (Cell Line: NCIH2122)	[5]
Gemcitabine + Ridaforolimus	DCQ2RYH	Ridaforolimus	Adenocarcinoma (Cell Line: NCIH520)	[5]
Gemcitabine + Ridaforolimus	DCZXMQE	Ridaforolimus	Adenocarcinoma (Cell Line: COLO320DM)	[5]
Gemcitabine + Ridaforolimus	DC7O8DW	Ridaforolimus	Adenocarcinoma (Cell Line: HT29)	[5]
Gemcitabine + Ridaforolimus	DCTN1R0	Ridaforolimus	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + Ridaforolimus	DC3EAKD	Ridaforolimus	Germ cell tumour (Cell Line: PA1)	[5]
Gemcitabine + Ridaforolimus	DCAV6P0	Ridaforolimus	Malignant melanoma (Cell Line: A375)	[5]
Gemcitabine + Ridaforolimus	DCGURKJ	Ridaforolimus	Malignant melanoma (Cell Line: RPMI7951)	[5]
Gemcitabine + Ridaforolimus	DCEK73S	Ridaforolimus	Prostate carcinoma (Cell Line: VCAP)	[5]
Gemcitabine + MK-4827	DCIO9JF	MK-4827	Adenocarcinoma (Cell Line: A427)	[5]
Gemcitabine + MK-4827	DC0N87Y	MK-4827	Adenocarcinoma (Cell Line: NCIH2122)	[5]
Gemcitabine + MK-4827	DC3VU2U	MK-4827	Adenocarcinoma (Cell Line: NCIH520)	[5]
Gemcitabine + MK-4827	DC9DXKQ	MK-4827	Adenocarcinoma (Cell Line: COLO320DM)	[5]
Gemcitabine + MK-4827	DC3W4FP	MK-4827	Adenocarcinoma (Cell Line: DLD1)	[5]
Gemcitabine + MK-4827	DCU4H8B	MK-4827	Adenocarcinoma (Cell Line: HT29)	[5]
Gemcitabine + MK-4827	DCUX19P	MK-4827	Adenocarcinoma (Cell Line: SW-620)	[5]
Gemcitabine + MK-4827	DCYWJ6D	MK-4827	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + MK-4827	DCM241T	MK-4827	Germ cell tumour (Cell Line: PA1)	[5]
Gemcitabine + MK-4827	DCDNWTF	MK-4827	Malignant melanoma (Cell Line: A375)	[5]
Gemcitabine + MK-4827	DCJC2GY	MK-4827	Malignant melanoma (Cell Line: HT144)	[5]
Gemcitabine + MK-4827	DCKPL66	MK-4827	Malignant melanoma (Cell Line: RPMI7951)	[5]
Gemcitabine + MK-4827	DCSWY0M	MK-4827	Malignant melanoma (Cell Line: SKMEL30)	[5]
Gemcitabine + MK-4827	DC82FHN	MK-4827	Malignant melanoma (Cell Line: UACC62)	[5]
Gemcitabine + MK-4827	DCJ2V12	MK-4827	Mesothelioma (Cell Line: MSTO)	[5]
Gemcitabine + MK-4827	DC3D3EC	MK-4827	Non small cell carcinoma (Cell Line: SKMES1)	[5]
Gemcitabine + MK-4827	DCPT2PP	MK-4827	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[5]
Gemcitabine + MK-4827	DCNQMX3	MK-4827	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Gemcitabine + MK-4827	DCFBC8F	MK-4827	Prostate carcinoma (Cell Line: VCAP)	[5]
Gemcitabine + Idarubicin	DC808JH	Idarubicin	Adenocarcinoma (Cell Line: CAOV3)	[5]
Gemcitabine + Idarubicin	DCELYS8	Idarubicin	Adenocarcinoma (Cell Line: NCIH2122)	[5]
Gemcitabine + Idarubicin	DCFYFDC	Idarubicin	Adenocarcinoma (Cell Line: NCIH23)	[5]
Gemcitabine + Idarubicin	DC54VPW	Idarubicin	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + Idarubicin	DC0TRQQ	Idarubicin	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Gemcitabine + Idarubicin	DCEQBXF	Idarubicin	Mesothelioma (Cell Line: MSTO)	[5]
Gemcitabine + Idarubicin	DCB2M9U	Idarubicin	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[5]
Gemcitabine + Bortezomib	DCMJ3WQ	Bortezomib	Adenocarcinoma (Cell Line: CAOV3)	[5]
Gemcitabine + Bortezomib	DCJV837	Bortezomib	Adenocarcinoma (Cell Line: OVCAR3)	[5]
Gemcitabine + Bortezomib	DC0GUCT	Bortezomib	Adenocarcinoma (Cell Line: NCIH2122)	[5]
Gemcitabine + Bortezomib	DC7CF5G	Bortezomib	Adenocarcinoma (Cell Line: NCIH520)	[5]
Gemcitabine + Bortezomib	DC60DXZ	Bortezomib	Adenocarcinoma (Cell Line: COLO320DM)	[5]
Gemcitabine + Bortezomib	DC4TJVI	Bortezomib	Adenocarcinoma (Cell Line: HT29)	[5]
Gemcitabine + Bortezomib	DCLNW5T	Bortezomib	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + Bortezomib	DC7A53A	Bortezomib	Malignant melanoma (Cell Line: RPMI7951)	[5]
Gemcitabine + Bortezomib	DC9SL2P	Bortezomib	Mesothelioma (Cell Line: MSTO)	[5]
Gemcitabine + Bortezomib	DCOWWGT	Bortezomib	Non small cell carcinoma (Cell Line: SKMES1)	[5]
Gemcitabine + Bortezomib	DC8XO78	Bortezomib	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[5]
Gemcitabine + PHA848125	DCURWEF	PHA848125	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Gemcitabine + Sorafenib	DCFSTPX	Sorafenib	Adenocarcinoma (Cell Line: DLD1)	[5]
Gemcitabine + Sorafenib	DC3H028	Sorafenib	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + Sorafenib	DCTGYID	Sorafenib	Malignant melanoma (Cell Line: HT144)	[5]
Gemcitabine + Sorafenib	DCQW9KD	Sorafenib	Mesothelioma (Cell Line: MSTO)	[5]
Gemcitabine + PF-562271	DCY79B5	PF-562271	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Gemcitabine + MK-2206	DC7QG7G	MK-2206	Adenocarcinoma (Cell Line: CAOV3)	[5]
Gemcitabine + MK-2206	DCOLOC8	MK-2206	Adenocarcinoma (Cell Line: A427)	[5]
Gemcitabine + MK-2206	DC6OSVF	MK-2206	Adenocarcinoma (Cell Line: NCIH2122)	[5]
Gemcitabine + MK-2206	DCVNLWT	MK-2206	Adenocarcinoma (Cell Line: NCIH520)	[5]
Gemcitabine + MK-2206	DCZ9LSZ	MK-2206	Adenocarcinoma (Cell Line: COLO320DM)	[5]
Gemcitabine + MK-2206	DCUA1HB	MK-2206	Adenocarcinoma (Cell Line: DLD1)	[5]
Gemcitabine + MK-2206	DCJ37TA	MK-2206	Adenocarcinoma (Cell Line: HT29)	[5]
Gemcitabine + MK-2206	DCIUG4I	MK-2206	Amelanotic melanoma (Cell Line: A2058)	[5]
Gemcitabine + MK-2206	DCPSN36	MK-2206	Germ cell tumour (Cell Line: PA1)	[5]
Gemcitabine + MK-2206	DC1RE8W	MK-2206	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Gemcitabine + MK-2206	DCUFLM8	MK-2206	Malignant melanoma (Cell Line: HT144)	[5]
Gemcitabine + MK-2206	DCTJX70	MK-2206	Malignant melanoma (Cell Line: RPMI7951)	[5]
Gemcitabine + MK-2206	DC9OA2U	MK-2206	Mesothelioma (Cell Line: MSTO)	[5]
Gemcitabine + MK-2206	DCUZQPU	MK-2206	Non small cell carcinoma (Cell Line: SKMES1)	[5]
Gemcitabine + MK-2206	DCANSG1	MK-2206	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Gemcitabine + MK-2206	DCNZLDF	MK-2206	Prostate carcinoma (Cell Line: VCAP)	[5]
Gemcitabine + CB3304	DCERTL1	CB3304	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Gemcitabine + Ibrutinib	DCY768L	Ibrutinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Gemcitabine + Dasatinib	DCHQIT0	Dasatinib	Adenocarcinoma (Cell Line: A427)	[5]
Gemcitabine + Dasatinib	DCR050M	Dasatinib	Adenocarcinoma (Cell Line: NCIH520)	[5]
Gemcitabine + Dasatinib	DC2FE0G	Dasatinib	Adenocarcinoma (Cell Line: DLD1)	[5]
Gemcitabine + Dasatinib	DCNUBF5	Dasatinib	Adenocarcinoma (Cell Line: HT29)	[5]
Gemcitabine + Dasatinib	DCS0YL8	Dasatinib	Germ cell tumour (Cell Line: PA1)	[5]
Gemcitabine + Dasatinib	DCERVFT	Dasatinib	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Gemcitabine + Dasatinib	DCEG5PH	Dasatinib	Malignant melanoma (Cell Line: A375)	[5]
Gemcitabine + Dasatinib	DCXI49M	Dasatinib	Mesothelioma (Cell Line: MSTO)	[5]
Gemcitabine + Dasatinib	DCBC4H2	Dasatinib	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[5]
Gemcitabine + Dasatinib	DC398ED	Dasatinib	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Gemcitabine + PD-0325901	DCK4MOL	PD-0325901	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[6]
Gemcitabine + PD-0325901	DCE2GMW	PD-0325901	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[6]
Gemcitabine + PD-0325901	DCN8J7R	PD-0325901	Breast carcinoma (Cell Line: KPL1)	[6]
Gemcitabine + PD-0325901	DCK39BP	PD-0325901	Breast carcinoma (Cell Line: OCUBM)	[6]
Gemcitabine + PD-0325901	DCK8FDZ	PD-0325901	Carcinoma (Cell Line: OV90)	[6]
Gemcitabine + PD-0325901	DC4C9RD	PD-0325901	Carcinoma (Cell Line: EFM192B)	[6]
Gemcitabine + PD-0325901	DCBMUKR	PD-0325901	Carcinoma (Cell Line: MDAMB436)	[6]
Gemcitabine + PD-0325901	DC7ZVP8	PD-0325901	Colon carcinoma (Cell Line: RKO)	[6]
Gemcitabine + PD-0325901	DCVVQP7	PD-0325901	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Gemcitabine + PD-0325901	DC0VRBS	PD-0325901	Rectal adenocarcinoma (Cell Line: SW837)	[6]
Gemcitabine + Lapatinib	DCX9C06	Lapatinib	Breast carcinoma (Cell Line: ZR751)	[6]
Gemcitabine + Lapatinib	DCLSOJT	Lapatinib	Breast carcinoma (Cell Line: OCUBM)	[6]
Gemcitabine + MK-1775	DC77MHE	MK-1775	Carcinoma (Cell Line: EFM192B)	[6]
Gemcitabine + MK-1775	DCN53RS	MK-1775	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Gemcitabine + RTB101	DCW1PJB	RTB101	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[6]
Gemcitabine + RTB101	DCR8JM3	RTB101	Breast carcinoma (Cell Line: OCUBM)	[6]
Gemcitabine + RTB101	DC4QGMK	RTB101	Carcinoma (Cell Line: EFM192B)	[6]
Gemcitabine + RTB101	DCWSH77	RTB101	Carcinoma (Cell Line: MDAMB436)	[6]
Gemcitabine + RTB101	DC9SRIU	RTB101	Colon carcinoma (Cell Line: RKO)	[6]
Gemcitabine + RTB101	DCJ475K	RTB101	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Gemcitabine + RTB101	DCZFPUN	RTB101	Rectal adenocarcinoma (Cell Line: SW837)	[6]
Gemcitabine + SCH-900776	DC1R3A5	SCH-900776	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[6]
Gemcitabine + SCH-900776	DCJ19QK	SCH-900776	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[6]
Gemcitabine + SCH-900776	DC5U3WA	SCH-900776	Breast carcinoma (Cell Line: OCUBM)	[6]
Gemcitabine + SCH-900776	DCINX8I	SCH-900776	Carcinoma (Cell Line: MDAMB436)	[6]
Gemcitabine + SCH-900776	DCZIMSV	SCH-900776	Colon adenocarcinoma (Cell Line: LOVO)	[6]
Gemcitabine + SCH-900776	DCI1KBE	SCH-900776	Colon carcinoma (Cell Line: RKO)	[6]
Gemcitabine + SCH-900776	DCIMMMU	SCH-900776	Rectal adenocarcinoma (Cell Line: SW837)	[6]
Gemcitabine + SNX-2112	DC9XM8T	SNX-2112	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[6]
Gemcitabine + SNX-2112	DC0CTFQ	SNX-2112	Rectal adenocarcinoma (Cell Line: SW837)	[6]
Gemcitabine + SCH 727965	DC5J4Q9	SCH 727965	Breast carcinoma (Cell Line: OCUBM)	[6]
Gemcitabine + SCH 727965	DCMWEZ8	SCH 727965	Carcinoma (Cell Line: MDAMB436)	[6]
Gemcitabine + Erlotinib	DCFGUY8	Erlotinib	Breast carcinoma (Cell Line: ZR751)	[6]
Gemcitabine + Erlotinib	DC1OXSA	Erlotinib	Breast carcinoma (Cell Line: KPL1)	[6]
Gemcitabine + Erlotinib	DCCCRVE	Erlotinib	Breast carcinoma (Cell Line: OCUBM)	[6]
Gemcitabine + Erlotinib	DC7WKBF	Erlotinib	Carcinoma (Cell Line: EFM192B)	[6]
Gemcitabine + Erlotinib	DCVGXBU	Erlotinib	Carcinoma (Cell Line: MDAMB436)	[6]
Gemcitabine + Erlotinib	DC0RDBN	Erlotinib	Colon carcinoma (Cell Line: RKO)	[6]
Gemcitabine + Erlotinib	DC2CYQX	Erlotinib	Rectal adenocarcinoma (Cell Line: SW837)	[6]
Gemcitabine + MK-5108	DCEYB2J	MK-5108	Carcinoma (Cell Line: EFM192B)	[6]
Gemcitabine + MK-5108	DCOI063	MK-5108	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Gemcitabine + Ridaforolimus	DC4W6G2	Ridaforolimus	Breast carcinoma (Cell Line: OCUBM)	[6]
Gemcitabine + Ridaforolimus	DCMXAYU	Ridaforolimus	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Gemcitabine + MK-4827	DCIO9VN	MK-4827	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[6]
Gemcitabine + MK-4827	DCPM4HL	MK-4827	Breast carcinoma (Cell Line: KPL1)	[6]
Gemcitabine + MK-4827	DCDYA05	MK-4827	Breast carcinoma (Cell Line: OCUBM)	[6]
Gemcitabine + MK-4827	DCIKB66	MK-4827	Carcinoma (Cell Line: EFM192B)	[6]
Gemcitabine + MK-4827	DC9ELYV	MK-4827	Carcinoma (Cell Line: MDAMB436)	[6]
Gemcitabine + MK-4827	DCW9446	MK-4827	Colon carcinoma (Cell Line: RKO)	[6]
Gemcitabine + MK-4827	DCV2RIU	MK-4827	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Gemcitabine + Bortezomib	DC1RSSH	Bortezomib	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[6]
Gemcitabine + Bortezomib	DCGQED7	Bortezomib	Carcinoma (Cell Line: MDAMB436)	[6]
Gemcitabine + Bortezomib	DC9NM8W	Bortezomib	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Gemcitabine + Sorafenib	DC3UJFN	Sorafenib	Breast carcinoma (Cell Line: ZR751)	[6]
Gemcitabine + MK-2206	DC66O4S	MK-2206	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[6]
Gemcitabine + MK-2206	DCH9HXV	MK-2206	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[6]
Gemcitabine + MK-2206	DCTUPR4	MK-2206	Breast carcinoma (Cell Line: OCUBM)	[6]
Gemcitabine + MK-2206	DCXYQO8	MK-2206	Carcinoma (Cell Line: EFM192B)	[6]
Gemcitabine + MK-2206	DCCWN1J	MK-2206	Carcinoma (Cell Line: MDAMB436)	[6]
Gemcitabine + MK-2206	DCRUE7G	MK-2206	Colon carcinoma (Cell Line: RKO)	[6]
Gemcitabine + MK-2206	DCCB7TE	MK-2206	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Gemcitabine + MK-2206	DCIV6TH	MK-2206	Rectal adenocarcinoma (Cell Line: SW837)	[6]
Gemcitabine + Dasatinib	DC85HEO	Dasatinib	Breast carcinoma (Cell Line: KPL1)	[6]
Gemcitabine + Dasatinib	DC8CLAK	Dasatinib	Breast carcinoma (Cell Line: OCUBM)	[6]
Gemcitabine + Dasatinib	DCUM3F2	Dasatinib	Carcinoma (Cell Line: MDAMB436)	[6]
Gemcitabine + Dasatinib	DCHTSP4	Dasatinib	Colon carcinoma (Cell Line: RKO)	[6]
MK-2206 + Gemcitabine	DCJIVV2	MK-2206	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
PMID28460551-Compound-2 + Gemcitabine	DCE0P88	PMID28460551-Compound-2	Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2)	[5]
PMID28460551-Compound-2 + Gemcitabine	DCITM4I	PMID28460551-Compound-2	Breast and ovarian cancer syndrome (Cell Line: UWB1289)	[6]
PMID28460551-Compound-2 + Gemcitabine	DC6EUC5	PMID28460551-Compound-2	Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1)	[6]
PMID28460551-Compound-2 + Gemcitabine	DCCYV6C	PMID28460551-Compound-2	Carcinoma (Cell Line: OV90)	[6]
PMID28460551-Compound-2 + Gemcitabine	DCSR1WA	PMID28460551-Compound-2	Carcinoma (Cell Line: MDAMB436)	[6]
PMID28460551-Compound-2 + Gemcitabine	DC2455R	PMID28460551-Compound-2	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
PMID28460551-Compound-2 + Gemcitabine	DCFUT49	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: OVCAR3)	[7]
PMID28460551-Compound-2 + Gemcitabine	DCBW24O	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: NCIH2122)	[7]
PMID28460551-Compound-2 + Gemcitabine	DCB1L1H	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: NCIH520)	[7]
PMID28460551-Compound-2 + Gemcitabine	DC4REBS	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: NCIH23)	[7]
PMID28460551-Compound-2 + Gemcitabine	DCHQ4H9	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: COLO320DM)	[7]
PMID28460551-Compound-2 + Gemcitabine	DC1F439	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: DLD1)	[7]
PMID28460551-Compound-2 + Gemcitabine	DCGIZTC	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: HT29)	[7]
PMID28460551-Compound-2 + Gemcitabine	DCI38YC	PMID28460551-Compound-2	Amelanotic melanoma (Cell Line: A2058)	[7]
PMID28460551-Compound-2 + Gemcitabine	DCTON42	PMID28460551-Compound-2	Germ cell tumour (Cell Line: PA1)	[7]
PMID28460551-Compound-2 + Gemcitabine	DCGW3D1	PMID28460551-Compound-2	Malignant melanoma (Cell Line: A375)	[7]
PMID28460551-Compound-2 + Gemcitabine	DC4L9J1	PMID28460551-Compound-2	Malignant melanoma (Cell Line: HT144)	[7]
PMID28460551-Compound-2 + Gemcitabine	DC5BU3B	PMID28460551-Compound-2	Malignant melanoma (Cell Line: RPMI7951)	[7]
PMID28460551-Compound-2 + Gemcitabine	DCTCDG8	PMID28460551-Compound-2	Malignant melanoma (Cell Line: SKMEL30)	[7]
PMID28460551-Compound-2 + Gemcitabine	DCGH59X	PMID28460551-Compound-2	Malignant melanoma (Cell Line: UACC62)	[7]
PMID28460551-Compound-2 + Gemcitabine	DCDIW81	PMID28460551-Compound-2	Mesothelioma (Cell Line: MSTO)	[7]
PMID28460551-Compound-2 + Gemcitabine	DCHKB0C	PMID28460551-Compound-2	Non small cell carcinoma (Cell Line: SKMES1)	[7]
PMID28460551-Compound-2 + Gemcitabine	DCLSEFU	PMID28460551-Compound-2	Ovarian endometrioid adenocarcinoma (Cell Line: A2780)	[7]
PMID28460551-Compound-2 + Gemcitabine	DCAV4LI	PMID28460551-Compound-2	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[7]
Prochlorperazine + Gemcitabine	DCWNFG6	Prochlorperazine	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]

118 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABT-888 + Gemcitabine	DCYGHPW	ABT-888	Pancreatic Cancer	[8]
AZD7762 + Gemcitabine	DCAR403	AZD7762	Cancer	[9]
CPI-613 + Gemcitabine	DC3AX0V	CPI-613	Cancer	[10]
Enzastaurin + Gemcitabine	DC261WU	Enzastaurin	Pancreatic Neoplasm	[11]
Gemcitabine + Docetaxel	DC2DM1F	Docetaxel	Breast Cancer	[12]
Gemcitabine + VATALANIB	DC3M780	VATALANIB	Pancreatic Cancer	[13]
Gemcitabine + Pazopanib	DC3XER7	Pazopanib	Lung Cancer, Non-Small Cell	[14]
Gemcitabine + Fludeoxyglucose F 18	DC44Q5V	Fludeoxyglucose F 18	Pancreatic Cancer	[15]
Gemcitabine + Decitabine	DC5ECSE	Decitabine	Pancreatic Cancer	[16]
Gemcitabine + TH-302	DC5OPE8	TH-302	Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma	[17]
Gemcitabine + Afatinib	DC5UQR8	Afatinib	Neoplasms	[18]
Gemcitabine + Pomalidomide	DC67HF0	Pomalidomide	Pancreatic Cancer	[19]
Gemcitabine + Vinorelbine	DC6PGA4	Vinorelbine	Breast Cancer	[20]
Gemcitabine + MK-8776	DCA7QCM	MK-8776	Hodgkin Disease	[21]
Gemcitabine + Tasisulam	DCAEJWW	Tasisulam	Advanced Solid Tumors	[22]
Gemcitabine + Masitinib	DCBIZ1V	Masitinib	Pancreatic Cancer	[23]
Gemcitabine + Oxaliplatin	DCCKCN9	Oxaliplatin	Cancer of the Head and Neck	[24]
Gemcitabine + Omaveloxolone	DCD6MTR	Omaveloxolone	Pancreatic Neoplasms	[25]
Gemcitabine + Erlotinib	DCDDX5Y	Erlotinib	Pancreatic Cancer	[26]
Gemcitabine + Pemetrexed	DCFE26I	Pemetrexed	Breast Cancer	[27]
Gemcitabine + Axitinib	DCGCBSA	Axitinib	Pancreatic Neoplasms	[28]
Gemcitabine + Cabozantinib	DCHGWKZ	Cabozantinib	Pancreatic Cancer	[29]
Gemcitabine + Dasatinib	DCIK2D1	Dasatinib	Refractory Solid Tumors	[30]
Gemcitabine + LY2090314	DCIY575	LY2090314	Pancreatic Cancer	[31]
Gemcitabine + Romidepsin	DCJRJEX	Romidepsin	Pancreatic Cancer	[32]
Gemcitabine + Pazopanib	DCKDMR5	Pazopanib	Bladder Cancer	[33]
Gemcitabine + Topotecan	DCLE5WV	Topotecan	Ovarian Cancer	[34]
Gemcitabine + Cabazitaxel	DCLTKD0	Cabazitaxel	Neoplasms, Malignant	[35]
Gemcitabine + LY2603618	DCMELAV	LY2603618	Pancreatic Neoplasms	[36]
Gemcitabine + Afatinib	DCMI4GF	Afatinib	Focus of Study Instead	[37]
Gemcitabine + Oxaliplatin	DCMP46P	Oxaliplatin	Lung Cancer	[38]
Gemcitabine + Vinflunine	DCOOWI2	Vinflunine	Bladder Cancer	[39]
Gemcitabine + Carboplatin	DCPK6PX	Carboplatin	Breast Cancer	[40]
Gemcitabine + Hydroxychloroquine	DCPQ42P	Hydroxychloroquine	Pancreatic Cancer	[41]
Gemcitabine + Pemetrexed	DCSFA8P	Pemetrexed	Lung Cancer	[42]
Gemcitabine + Chloroquine	DCSRX1T	Chloroquine	Pancreatic Cancer	[43]
Gemcitabine + LY2157299	DCTUMXU	LY2157299	Neoplasms	[44]
Gemcitabine + Sodium bicarbonate	DCU4K07	Sodium bicarbonate	Pancreatic Cancer	[45]
Gemcitabine + Paclitaxel	DCUMAK5	Paclitaxel	Head and Neck Cancer	[46]
Gemcitabine + Sunitinib	DCV7R5U	Sunitinib	Renal Cell Carcinoma	[47]
Gemcitabine + Bay 86-9766	DCW33WB	Bay 86-9766	Neoplasms	[48]
Gemcitabine + Rigosertib	DCXPFSI	Rigosertib	Malignant Neoplasmas	[49]
Gemcitabine + Irinotecan	DCYE274	Irinotecan	Neoplasms, Unknown Primary	[50]
Gemcitabine + Aflibercept	DCYMOOT	Aflibercept	Pancreatic Neoplasm	[51]
Gemcitabine + Capecitabine	DCYTOJ2	Capecitabine	Pancreatic Cancer	[52]
Gemcitabine + GI-4000	DCRRUX2	GI-4000	Pancreatic cancer	[53]
Gemcitabine + Aldoxorubicin	DC4WER4	Aldoxorubicin	Metastatic Solid Tumors	[54]
Gemcitabine + LY2603618	DCJIJ1U	LY2603618	Cancer	[55]
Gemcitabine + Docetaxel	DC0A2KP	Docetaxel	Stage III Adult Soft Tissue Sarcoma	[56]
Gemcitabine + Valganciclovir	DC4LFVQ	Valganciclovir	Nasopharyngeal Carcinoma	[57]
Gemcitabine + Imatinib	DC6J2FO	Imatinib	Advanced Pancreatic Cancer	[58]
Gemcitabine + Vandetanib	DCHRXVN	Vandetanib	Malignant Solid Tumour	[59]
Gemcitabine + Oxaliplatin	DCI5L9F	Oxaliplatin	Advanced Incurable Solid Malignancy	[60]
Gemcitabine + Docetaxel	DCPEA51	Docetaxel	Pancreatic Cancer	[61]
Gemcitabine + Erlotinib	DCSTD1Q	Erlotinib	Metastatic Pancreatic Carcinoma	[62]
Gemcitabine + LY2603618	DCW2ZVG	LY2603618	Advanced Cancer	[63]
Gemcitabine + Oxaliplatin	DCWSX36	Oxaliplatin	Advanced Gastrointestinal Malignancies	[64]
Gemcitabine + Bay 80-6946	DC85H4S	Bay 80-6946	Mature T-Cell and NK-Cell Neoplasm	[65]
Gemcitabine + LEE011	DC995TY	LEE011	Anaplastic Astrocytoma	[66]
Gemcitabine + Tadalafil	DCH2UVW	Tadalafil	Locally Advanced Malignant Neoplasm	[67]
Gemcitabine + VX-970	DCP8VKF	VX-970	Advanced Solid Tumor	[68]
Gemcitabine + TH-302	DCVBI4G	TH-302	Solid Tumor	[69]
Gemcitabine + LY2835219	DCWQDSF	LY2835219	Carcinoma, Non-small Cell Lung	[70]
Icotinib hydrochloride + Gemcitabine	DCE84A5	Icotinib hydrochloride	Pancreatic Cancer	[71]
Imiquimod + Gemcitabine	DCK4MLQ	Imiquimod	Sarcoma	[72]
Lapatinib + Gemcitabine	DC8TZKW	Lapatinib	Metastatic Pancreatic Cancer	[73]
Lapatinib + Gemcitabine	DCSWME9	Lapatinib	Metastatic Pancreatic Cancer	[73]
Larotrectinib + Gemcitabine	DCA9BXQ	Larotrectinib	Pancreatic Cancer	[74]
Lenalidomide + Gemcitabine	DCCAFIK	Lenalidomide	Metastatic Pancreatic Cancer	[75]
LY2606368 + Gemcitabine	DCKP9JQ	LY2606368	Brain Tumor	[76]
MK-1775 + Gemcitabine	DCENERW	MK-1775	Solid Tumors	[77]
Ruxolitinib + Gemcitabine	DC0Q6IB	Ruxolitinib	Solid Tumors	[78]
Talazoparib + Gemcitabine	DCXHMWM	Talazoparib	Acute Myeloid Leukemia	[79]
Trametinib + Gemcitabine	DC244C2	Trametinib	Cancer	[80]
Vismodegib + Gemcitabine	DCTJAD8	Vismodegib	Pancreatic Adenocarcinoma Resectable	[81]
Belinostat + Gemcitabine	DC2JB7Q	Belinostat	PTCL	[82]
Cyclophosphamide + Gemcitabine	DCENLKG	Cyclophosphamide	Acute Lymphoblastic Leukemia, Adult	[83]
Dexamethasone + Gemcitabine	DCBXCFI	Dexamethasone	Intrahepatic Cholangiocarcinoma	[84]
Dexamethasone + Gemcitabine	DCGLQE5	Dexamethasone	Hodgkin's Lymphoma	[85]
Eribulin + Gemcitabine	DCUQQ1R	Eribulin	Metastatic Breast Cancer	[86]
Gemcitabine + Docetaxel	DC38QMC	Docetaxel	Carcinoma, Non-Small-Cell Lung	[87]
Gemcitabine + Erlotinib	DC3AA12	Erlotinib	Pancreatic Adenocarcinoma	[88]
Gemcitabine + Docetaxel	DC4EPQ1	Docetaxel	Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	[89]
Gemcitabine + Docetaxel	DC79PW1	Docetaxel	Pancreatic Cancer	[90]
Gemcitabine + Erlotinib	DCAEE26	Erlotinib	Pancreatic Cancer	[91]
Gemcitabine + Oxaliplatin	DCAX0X4	Oxaliplatin	Pancreatic Cancer	[92]
Gemcitabine + Docetaxel	DCC81JT	Docetaxel	Non-small Cell Lung Cancer	[93]
Gemcitabine + Docetaxel	DCKBNU3	Docetaxel	Breast Cancer	[94]
Gemcitabine + Carboplatin	DCNX3HZ	Carboplatin	Lung Cancer	[95]
Gemcitabine + Carboplatin	DCS5S8P	Carboplatin	Triple Negative Breast Cancer	[96]
Gemcitabine + Erlotinib	DCSULYL	Erlotinib	Locally Advanced Pancreatic Cancer	[97]
Gemcitabine + Docetaxel	DCZ6U23	Docetaxel	Lung Cancer	[98]
Gemcitabine + Paricalcitol	DC672F6	Paricalcitol	Advanced Pancreatic Cancer	[99]
Gemcitabine + Vinflunine	DC7LGYF	Vinflunine	Urothelial Carcinoma	[100]
Gemcitabine + Irinotecan	DCIUFM5	Irinotecan	Pancreatic Cancer	[101]
Gemcitabine + Masitinib	DCIZGP5	Masitinib	Ovarian Cancer	[102]
Gemcitabine + Tivozanib	DCPWF2J	Tivozanib	Renal Cell Carcinoma	[103]
Gemcitabine + Lurbinectedin	DCPZVML	Lurbinectedin	Non-Small Cell Lung Cancer (NSCLC)	[104]
Gemcitabine + RQ-00000007 (oral)	DCRFKER	RQ-00000007 (oral)	Prostate Cancer	[105]
Gemcitabine + Capecitabine	DCS4MQD	Capecitabine	Pancreatic Cancer	[106]
Gemcitabine + Metformin	DCSHKOR	Metformin	Stage IA Pancreatic Adenocarcinoma	[107]
Gemcitabine + Imatinib	DCV773C	Imatinib	Mesothelioma, Malignant	[108]
Gemcitabine + Vinorelbine	DCXCWIM	Vinorelbine	Hodgkin's Lymphoma	[109]
MGCD-0103 + Gemcitabine	DC4M3CV	MGCD-0103	Metastatic Leiomyosarcoma	[110]
Rivoceranib + Gemcitabine	DCW6X2P	Rivoceranib	Metastatic Pancreatic Cancer	[111]
Selinexor + Gemcitabine	DC71208	Selinexor	Sarcoma,Soft Tissue	[112]
Tegafur + Gemcitabine	DC1NYL8	Tegafur	Biliary Tract Neoplasms	[113]
Tegafur + Gemcitabine	DC1AOOC	Tegafur	Stage IA Pancreatic Adenocarcinoma	[114]
Eribulin + Gemcitabine	DC78YPN	Eribulin	Metastatic Breast Cancer	[115]
Eribulin + Gemcitabine	DC8M7UB	Eribulin	Metastatic Triple Negative Breast Cancer	[116]
Eribulin + Gemcitabine	DCHPHFG	Eribulin	Breast Cancer	[117]
Gemcitabine + Docetaxel	DC7IH5M	Docetaxel	Advanced Non-Small Cell Lung Cancer	[118]
Gemcitabine + Docetaxel	DC7N6IM	Docetaxel	Nasopharyngeal Neoplasms	[119]
Gemcitabine + Erlotinib	DCH3LJR	Erlotinib	Non - Small Cell Lung Cancer NSCLC	[120]
Gemcitabine + Pralatrexate	DCPAU0W	Pralatrexate	Relapsed Peripheral T-Cell Lymphoma	[121]
Gemcitabine + Mitomycin	DCJP1NF	Mitomycin	Non-Muscle Invasive Bladder Neoplasms	[122]
Gemcitabine + Oxaliplatin	DCOQO10	Oxaliplatin	Diffuse Large B-Cell Lymphoma	[123]
Gemcitabine + Romidepsin	DCPJTMZ	Romidepsin	Relapsed Angioimmunoblastic T-Cell Lymphoma	[124]

References

• [1] Gemcitabine FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4793).
• [4] Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
• [5] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [6] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
• [7] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [8] ClinicalTrials.gov (NCT01908478) Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer
• [9] ClinicalTrials.gov (NCT00937664) Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
• [10] ClinicalTrials.gov (NCT00907166) A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
• [11] ClinicalTrials.gov (NCT00267020) Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer
• [12] ClinicalTrials.gov (NCT00191152) A Phase III Trial For Patients With Metastatic Breast Cancer
• [13] ClinicalTrials.gov (NCT00185588) Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
• [14] ClinicalTrials.gov (NCT00678977) A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors
• [15] ClinicalTrials.gov (NCT01146054) Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
• [16] ClinicalTrials.gov (NCT02685228) Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer
• [17] ClinicalTrials.gov (NCT01746979) Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
• [18] ClinicalTrials.gov (NCT01251653) A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel
• [19] ClinicalTrials.gov (NCT00540579) CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas
• [20] ClinicalTrials.gov (NCT00128310) Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
• [21] ClinicalTrials.gov (NCT00779584) A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248). U.S. National Institutes of Health.
• [22] ClinicalTrials.gov (NCT01284335) A Safety Study in Participants With Advanced Solid Tumors
• [23] ClinicalTrials.gov (NCT00789633) Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
• [24] ClinicalTrials.gov (NCT00256295) Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer
• [25] ClinicalTrials.gov (NCT00529113) Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
• [26] ClinicalTrials.gov (NCT00461708) A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
• [27] ClinicalTrials.gov (NCT00063570) Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy
• [28] ClinicalTrials.gov (NCT00219557) AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
• [29] ClinicalTrials.gov (NCT01663272) A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
• [30] ClinicalTrials.gov (NCT00598091) A Phase I/Expansion Study of Dasatinib
• [31] ClinicalTrials.gov (NCT01632306) A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
• [32] ClinicalTrials.gov (NCT00379639) A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors
• [33] ClinicalTrials.gov (NCT01622660) Gemcitabine and Pazopanib in Chemotherapy Nave Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
• [34] ClinicalTrials.gov (NCT00429559) Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
• [35] ClinicalTrials.gov (NCT01001221) Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
• [36] ClinicalTrials.gov (NCT00839332) A Study for Participants With Pancreatic Cancer
• [37] ClinicalTrials.gov (NCT01728818) Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours
• [38] ClinicalTrials.gov (NCT00452881) Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC
• [39] ClinicalTrials.gov (NCT00389155) First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
• [40] ClinicalTrials.gov (NCT00191451) A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer
• [41] ClinicalTrials.gov (NCT01128296) Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
• [42] ClinicalTrials.gov (NCT00193414) Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer
• [43] ClinicalTrials.gov (NCT01777477) Adjuvant Effect of Chloroquine on Gemcitabine
• [44] ClinicalTrials.gov (NCT01373164) A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
• [45] ClinicalTrials.gov (NCT01198821) Gem-TABS in Unresectable Pancreatic Carcinoma
• [46] ClinicalTrials.gov (NCT00100789) S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
• [47] ClinicalTrials.gov (NCT00556049) Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
• [48] ClinicalTrials.gov (NCT01764828) BAY86-9766 Plus Gemcitabine Phase I Study in Asian
• [49] ClinicalTrials.gov (NCT01125891) Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
• [50] ClinicalTrials.gov (NCT00193596) Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
• [51] ClinicalTrials.gov (NCT00574275) Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
• [52] ClinicalTrials.gov (NCT00626158) Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
• [53] Clinical pipeline report, company report or official report of GlobeImmune.
• [54] ClinicalTrials.gov (NCT02235688) Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
• [55] ClinicalTrials.gov (NCT01358968) A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
• [56] ClinicalTrials.gov (NCT01719302) Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
• [57] ClinicalTrials.gov (NCT02761291) Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
• [58] ClinicalTrials.gov (NCT01048320) Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer
• [59] ClinicalTrials.gov (NCT00551096) Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
• [60] ClinicalTrials.gov (NCT00660725) Study of GemOx and Vandetanib in Advanced Solid Malignancy
• [61] ClinicalTrials.gov (NCT00320749) Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
• [62] ClinicalTrials.gov (NCT00480584) A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
• [63] ClinicalTrials.gov (NCT01296568) C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
• [64] ClinicalTrials.gov (NCT00660426) Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors
• [65] ClinicalTrials.gov (NCT03052933) Copanlisib and Gemcitabine in Relapsed/Refractory PTCL
• [66] ClinicalTrials.gov (NCT03434262) SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
• [67] ClinicalTrials.gov (NCT01903083) Chemoimmunotherapy and Radiation in Pancreatic Cancer
• [68] ClinicalTrials.gov (NCT02157792) M6620 First in Human Study
• [69] ClinicalTrials.gov (NCT01833546) A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
• [70] ClinicalTrials.gov (NCT02079636) A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
• [71] ClinicalTrials.gov (NCT02278458) Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
• [72] ClinicalTrials.gov (NCT01803152) Dendritic Cell Vaccine for Children and Adults With Sarcoma
• [73] ClinicalTrials.gov (NCT00447122) BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
• [74] ClinicalTrials.gov (NCT04131192) Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
• [75] ClinicalTrials.gov (NCT00837031) Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
• [76] ClinicalTrials.gov (NCT04023669) Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
• [77] ClinicalTrials.gov (NCT00648648) A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
• [78] ClinicalTrials.gov (NCT01822756) An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
• [79] ClinicalTrials.gov (NCT05101551) Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
• [80] ClinicalTrials.gov (NCT01231581) Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
• [81] ClinicalTrials.gov (NCT01713218) Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer
• [82] ClinicalTrials.gov (NCT04747236) Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
• [83] ClinicalTrials.gov (NCT03339700) Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia
• [84] ClinicalTrials.gov (NCT01862315) Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
• [85] ClinicalTrials.gov (NCT03615664) The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD
• [86] ClinicalTrials.gov (NCT02263495) Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer
• [87] ClinicalTrials.gov (NCT00215930) The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
• [88] ClinicalTrials.gov (NCT00728000) Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
• [89] ClinicalTrials.gov (NCT03041181) Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
• [90] ClinicalTrials.gov (NCT00882310) A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
• [91] ClinicalTrials.gov (NCT00564720) Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer
• [92] ClinicalTrials.gov (NCT00408564) Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
• [93] ClinicalTrials.gov (NCT01774578) Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
• [94] ClinicalTrials.gov (NCT00193050) Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
• [95] ClinicalTrials.gov (NCT00226590) Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC
• [96] ClinicalTrials.gov (NCT04464174) Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer
• [97] ClinicalTrials.gov (NCT01210911) Metformin Combined With Chemotherapy for Pancreatic Cancer
• [98] ClinicalTrials.gov (NCT00193427) Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
• [99] ClinicalTrials.gov (NCT04617067) Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer
• [100] ClinicalTrials.gov (NCT02665039) A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function
• [101] ClinicalTrials.gov (NCT02405585) Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
• [102] ClinicalTrials.gov (NCT02490488) Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients
• [103] ClinicalTrials.gov (NCT01834183) Tivozanib + Gemcitabine in Metastatic RCC
• [104] ClinicalTrials.gov (NCT01951157) A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
• [105] ClinicalTrials.gov (NCT02538432) Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
• [106] ClinicalTrials.gov (NCT02767752) Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer
• [107] ClinicalTrials.gov (NCT02005419) Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection
• [108] ClinicalTrials.gov (NCT02303899) Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma
• [109] ClinicalTrials.gov (NCT01884441) Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
• [110] ClinicalTrials.gov (NCT02303262) SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
• [111] ClinicalTrials.gov (NCT02863367) A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer
• [112] ClinicalTrials.gov (NCT06114004) Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
• [113] ClinicalTrials.gov (NCT03406299) Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
• [114] ClinicalTrials.gov (NCT04216758) Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer
• [115] ClinicalTrials.gov (NCT03901339) Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer
• [116] ClinicalTrials.gov (NCT02555657) Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
• [117] ClinicalTrials.gov (NCT02574455) Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
• [118] ClinicalTrials.gov (NCT00345059) The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer
• [119] ClinicalTrials.gov (NCT02611960) Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
• [120] ClinicalTrials.gov (NCT02352948) A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
• [121] ClinicalTrials.gov (NCT01482962) Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
• [122] ClinicalTrials.gov (NCT06211764) A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Gurin (BCG)
• [123] ClinicalTrials.gov (NCT02951156) Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
• [124] ClinicalTrials.gov (NCT03593018) Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL